Efficacy and safety of exenatide once weekly: an overview of the DURATION trials

References

• Madsbad S. Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics) – preclinical and clinical results. Best Pract. Res. Clin. Endocrinol. Metab. 23(4), 463–477 (2009).
   PubMed Web of Science ®Google Scholar
• Blonde L, Russell-Jones D. The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in Type 2 diabetes: an overview of the LEAD 1–5 studies. Diabetes Obes. Metab. 11(Suppl. 3), 26–34 (2009).
   PubMed Web of Science ®Google Scholar
• Peters A. Incretin-based therapies: review of current clinical trial data. Am. J. Med. 123(Suppl. 3), S28–S37 (2010).
   PubMed Web of Science ®Google Scholar
• Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG; GWAA Study Group. Exenatide versus insulin glargine in patients with suboptimally controlled Type 2 diabetes: a randomized trial. Ann. Intern. Med. 143(8), 559–569 (2005).
   PubMed Web of Science ®Google Scholar
• Nauck MA, Duran S, Kim D et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with Type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 50(2), 259–267 (2007).
   PubMed Web of Science ®Google Scholar
• Barnett AH, Burger J, Johns D et al. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with Type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin. Ther. 29(11), 2333–2348 (2007).
   PubMed Web of Science ®Google Scholar
• Russell-Jones D, Vaag A, Schmitz O et al.; Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in Type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 52(10), 2046–2055 (2009).
   PubMed Web of Science ®Google Scholar
• Kim D, MacConell L, Zhuang D et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with Type 2 diabetes. Diabetes Care 30(6), 1487–1493 (2007).
   PubMed Web of Science ®Google Scholar
• Malone J, Trautmann M, Wilhelm K, Taylor K, Kendall DM. Exenatide once weekly for the treatment of Type 2 diabetes. Expert Opin. Investig. Drugs 18(3), 359–367 (2009).
   PubMed Web of Science ®Google Scholar
• Tracy MA, Ward KL, Firouzabadian L et al. Factors affecting the degradation rate of poly(lactide-co-glycolide) microspheres in vivo and in vitro. Biomaterials 20(11), 1057–1062 (1999).
   PubMed Web of Science ®Google Scholar
• Drucker DJ, Buse JB, Taylor K et al.; DURATION-1 Study Group. Exenatide once weekly versus twice daily for the treatment of Type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 372(9645), 1240–1250 (2008).
   PubMed Web of Science ®Google Scholar
• Buse JB, Drucker DJ, Taylor KL et al.; DURATION-1 Study Group. DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care 33(6), 1255–1261 (2010).
   PubMed Web of Science ®Google Scholar
• Taylor K, Gurney K, Han J, Pencek R, Walsh B, Trautmann M. Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years. BMC Endocr. Disord. 11, 9 (2011).
   PubMed Web of Science ®Google Scholar
• Bergenstal RM, Wysham C, Macconell L et al.; DURATION-2 Study Group. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of Type 2 diabetes (DURATION-2): a randomised trial. Lancet 376(9739), 431–439 (2010).
   PubMed Web of Science ®Google Scholar
• Wysham C, Bergenstal R, Malloy J et al. DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide. Diabet. Med. 28(6), 705–714 (2011).
   PubMed Web of Science ®Google Scholar
• Diamant M, Van Gaal L, Stranks S et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with Type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 375(9733), 2234–2243 (2010).
   PubMed Web of Science ®Google Scholar
• Russell-Jones D, Cuddihy RM, Hanefeld M et al.; DURATION-4 Study Group. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with Type 2 diabetes (DURATION-4): a 26-week double-blind study. Diabetes Care 35(2), 252–258 (2012).
   PubMed Web of Science ®Google Scholar
• Blevins T, Pullman J, Malloy J et al. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with Type 2 diabetes. J. Clin. Endocrinol. Metab. 96(5), 1301–1310 (2011).
   PubMed Web of Science ®Google Scholar
• Buse JB, Nauck M, Forst T et al. Efficacy and safety of exenatide oncy weekly versus liraglutide in subjects with Type 2 diabetes (DURATION-6): a randomized, open-label study. Diabetologia 54(Suppl. 1), S38 (2011).
   Google Scholar
• Best JH, Boye KS, Rubin RR, Cao D, Kim TH, Peyrot M. Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily. Diabet. Med. 26(7), 722–728 (2009).
   PubMed Web of Science ®Google Scholar
• Fineman MS, Mace KF, Diamant M et al. Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment. Diabetes. Obes. Metab. 14(6), 546–554 (2012).
   PubMed Web of Science ®Google Scholar
• Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocr. Rev. 33(2), 187–215 (2012).
   PubMed Web of Science ®Google Scholar
• Butler PC, Dry S, Elashoff R. GLP-1-based therapy for diabetes: what you do not know can hurt you. Diabetes Care 33(2), 453–455 (2010).
   PubMed Web of Science ®Google Scholar
• Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 141(1), 150–156 (2011).
   PubMed Web of Science ®Google Scholar
• Wenten M, Gaebler JA, Hussein M et al. Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: a follow-up study. Diabet. Med. 29(11), 1412–1418 (2012).
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB et al.; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in Type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 35(6), 1364–1379 (2012).
   PubMed Web of Science ®Google Scholar
• Rodbard HW, Jellinger PS, Davidson JA et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on Type 2 diabetes mellitus: an algorithm for glycemic control. Endocr. Pract. 15(6), 540–559 (2009).
   PubMed Web of Science ®Google Scholar
• Bhattacharyya OK, Estey EA, Cheng AY; Canadian Diabetes Association 2008. Update on the Canadian Diabetes Association 2008 clinical practice guidelines. Can. Fam. Physician 55(1), 39–43 (2009).
   PubMed Web of Science ®Google Scholar
• Adler AI, Shaw EJ, Stokes T, Ruiz F; Guideline Development Group. Newer agents for blood glucose control in Type 2 diabetes: summary of NICE guidance. BMJ 338, b1668 (2009).
   Google Scholar
• Kielgast U, Holst JJ, Madsbad S. Treatment of Type 1 diabetic patients with glucagon-like peptide-1 (GLP-1) and GLP-1R agonists. Curr. Diabetes Rev. 5(4), 266–275 (2009).
   PubMedGoogle Scholar
• Raman VS, Mason KJ, Rodriguez LM et al. The role of adjunctive exenatide therapy in pediatric Type 1 diabetes. Diabetes Care 33(6), 1294–1296 (2010).
   PubMed Web of Science ®Google Scholar
• Kielgast U, Krarup T, Holst JJ, Madsbad S. Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in Type 1 diabetic patients with and without residual b-cell function. Diabetes Care 34(7), 1463–1468 (2011).
   PubMed Web of Science ®Google Scholar
• Varanasi A, Bellini N, Rawal D et al. Liraglutide as additional treatment for Type 1 diabetes. Eur. J. Endocrinol. 165(1), 77–84 (2011).
   PubMed Web of Science ®Google Scholar